FDA clears Cervarix for 10- to 25-year-old females

10/18/2009 | WebMD

GlaxoSmithKline has won FDA approval for the use of human papillomavirus vaccine Cervarix in girls ages 10 to 25. The decision is based on clinical trials that demonstrated that Cervarix was 93% effective in protecting patients in the age group from cervical precancers associated with HPV 16 or HPV 18 strains.

View Full Article in:

WebMD

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN